Our data suggests that MerTK overexpression on the TNBC tumor leads to robust increases in anti-tumor immune infiltrate, cytotoxic lymphocyte activation, immune-mediated tumor killing, and remarkable tumor control in murine models, in some cases complete tumor regression without recurrence, when treated with ICI. This evidence concerns the gene MERTK and neoplasm.